Neurocrine Biosciences, Inc. (BIT:1NBIX)

Market Cap	10.94B +10.9%
Revenue (ttm)	2.44B +21.4%
Net Income	407.62M +40.2%
EPS	3.98 +41.9%
Shares Out	n/a
PE Ratio	26.85
Forward PE	15.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	14
Open	n/a
Previous Close	110.25
Day's Range	n/a
52-Week Range	92.16 - 145.95
Beta	n/a
RSI	45.63
Earnings Date	May 5, 2026

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical develo...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1992
• Employees: 2,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1NBIX

Financial Performance

In 2025, Neurocrine Biosciences's revenue was $2.86 billion, an increase of 21.45% compared to the previous year's $2.36 billion. Earnings were $478.60 million, an increase of 40.23%.

Financial numbers in USD